thromboxane-a2 and No-Reflow-Phenomenon

To investigate the influence of dexmedetomidine on myocardial ischemia-reperfusion injury (IRI) in rabbits.. Twenty-four New Zealand white rabbits were randomly divided into two equal-sized groups: IRI group (group IR) and dexmedetomidine group (group D). Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), left ventricular diastolic pressure (LVDP), +dp/dtmax, -dp/dtmax, and t-dp/dtmax were recorded and calculated at the following time points: before (T0) and after (T1) dexmedetomidine infusion, after 30-min ischemia (T2), and after 120-min reperfusion (T3). The levels of plasma endothelin 1 (ET-1), thromboxane A2 (TXA2), and platelet activating factor (PAF); area of myocardial infarction (MI); and no-reflow area were evaluated.. SBP, DBP, LVSP, LVEDP, LVDP, and +dp/dtmax at T3 were higher in group D than in group IR (P<0.05). The average no-reflow area in group IR was significantly smaller than that in group D (14±3% vs. 38±5%, P=0.0116). The ET-1, TXA2, and PAF levels at T2 and T3 were higher than those at T0 in both groups (P<0.05).. Dexmedetomidine could reduce the magnitude of ischemic myocardial no-reflow area and protect the myocardium with ischemia-reperfusion injury.

Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Endothelin-1; Heart Rate; Hemodynamics; Male; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Platelet Activating Factor; Rabbits; Random Allocation; Reference Values; Reproducibility of Results; Thromboxane A2; Treatment Outcome

Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI).. A total of 47 consecutive patients (age, 62.5 +/- 12.7; male sex, 76.6%) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of

Topics: Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Circulation; Electrocardiography; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Risk Assessment; Thromboxane A2; Treatment Outcome

Topics: Angioplasty, Balloon, Coronary; Coronary Circulation; Humans; Myocardial Infarction; No-Reflow Phenomenon; Receptors, Thromboxane A2, Prostaglandin H2; Thromboxane A2